Previous 10 | Next 10 |
2024-05-31 03:30:00 ET Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors. *Stock prices used were the afternoon prices of May 28, 2024. The video was published on May 30, 2024. Continue reading For further de...
2024-05-30 16:10:00 ET Summary The global market for GLP-1 therapies now looks on pace to top $100 billion. GLP-1 pioneers such as Eli Lilly, Novo Nordisk, could be joined by new players Amgen, Altimmune, Pfizer, Viking, Roche, and privately held Boehringer Ingelheim that have GLP...
2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...
2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...
2024-05-30 09:00:00 ET Summary Markets spooked by the Fed's language on inflation progress, causing uncertainty on rate cuts. Dividend Harvesting Portfolio retraces slightly but still generates respectable dividend income. Portfolio composition shows diversification and focus ...
2024-05-30 07:04:27 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Moderna down ~9%, likely ending 10-sessio...
2024-05-29 17:44:01 ET Summary ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overcome resistance to other standard-of-care treatments...
2024-05-29 17:11:50 ET More on BridgeBio Pharma BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident Cantor picks 14 undervalued biotech stocks worth a second look BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of ...
2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...
2024-05-29 10:07:00 ET As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with billions of dollars devoted to research and development, it...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...